<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0018660"><a href="http://purl.obolibrary.org/obo/MONDO_0018660">MONDO:0018660</a></h3>
<p><strong>Label:</strong> hemophilia</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0010602">MONDO:0010602</a> (hemophilia a), <a href="http://purl.obolibrary.org/obo/MONDO_0010604">MONDO:0010604</a> (hemophilia b),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://purl.obolibrary.org/obo/OMIM_306700">OMIM:306700</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98878">Orphanet:98878</a>, <a href="http://www.orpha.net/ORDO/Orphanet_98879">Orphanet:98879</a>, <a href="http://purl.obolibrary.org/obo/OMIM_306900">OMIM:306900</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011029">HP:0011029</a> (Internal hemorrhage) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011028">HP:0011028</a> (Abnormality of blood circulation) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011025">HP:0011025</a> (Abnormality of cardiovascular system physiology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0010989">HP:0010989</a> (Abnormality of the intrinsic pathway) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0005261">HP:0005261</a> (Joint hemorrhage) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001892">HP:0001892</a> (Abnormal bleeding) and <a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001626">HP:0001626</a> (Abnormality of the cardiovascular system) and <a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011029">HP:0011029</a> (Internal hemorrhage) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011028">HP:0011028</a> (Abnormality of blood circulation) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011025">HP:0011025</a> (Abnormality of cardiovascular system physiology) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0010989">HP:0010989</a> (Abnormality of the intrinsic pathway) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0005261">HP:0005261</a> (Joint hemorrhage) and <a href="http://purl.obolibrary.org/obo/HP_0010989">HP:0010989</a> (Abnormality of the intrinsic pathway) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003256">HP:0003256</a> (Abnormality of the coagulation cascade) and <a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0005261">HP:0005261</a> (Joint hemorrhage) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001892">HP:0001892</a> (Abnormal bleeding) and <a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001626">HP:0001626</a> (Abnormality of the cardiovascular system) and <a href="http://purl.obolibrary.org/obo/HP_0003645">HP:0003645</a> (Prolonged partial thromboplastin time) and <a href="http://purl.obolibrary.org/obo/HP_0011842">HP:0011842</a> (Abnormality of skeletal morphology) 87.50%</li>
</ul>
</body>
</html>
